Compounds > erlotinib hydrochloride
Page last updated: 2024-09-05

erlotinib hydrochloride and Carcinoma, Ovarian Epithelial

erlotinib hydrochloride has been researched along with Carcinoma, Ovarian Epithelial in 4 studies

Research

Studies (4)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's3 (75.00)24.3611
2020's1 (25.00)2.80

Authors

AuthorsStudies
Poursheikhani, A; Seyed H, G; Tavakoli-Bazzaz, J; Yousefi, H1
Klempner, SJ; Mills, GB; Myers, AP; Westin, SN1
Buck, M; Casado, A; Coens, C; Colombo, N; Curé, H; Despierre, E; Favier, L; Ferrero, A; Green, J; Hall, M; Jimeno, A; Joly, F; Katsaros, D; Lesoin, A; Marth, C; Pujade-Lauraine, E; Ray-Coquard, I; Reed, NS; Reinthaller, A; Steer, CB; Vergote, IB1
Gui, T; Shen, K1

Reviews

2 review(s) available for erlotinib hydrochloride and Carcinoma, Ovarian Epithelial

ArticleYear
Clinical investigation of receptor and non-receptor tyrosine kinase inhibitors for the treatment of epithelial ovarian cancer.
    Expert opinion on pharmacotherapy, 2013, Volume: 14, Issue:16

    Topics: Antineoplastic Agents; Benzodioxoles; Carcinoma, Ovarian Epithelial; Erlotinib Hydrochloride; Female; Humans; Indazoles; Indoles; Neoplasms, Glandular and Epithelial; Neovascularization, Pathologic; Ovarian Neoplasms; Protein Kinase Inhibitors; Pyrimidines; Quinazolines; Sulfonamides

2013
The epidermal growth factor receptor as a therapeutic target in epithelial ovarian cancer.
    Cancer epidemiology, 2012, Volume: 36, Issue:5

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Cetuximab; Drug Resistance, Neoplasm; Enzyme Activation; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Molecular Targeted Therapy; Mutation; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Panitumumab; Protein-Tyrosine Kinases; Quinazolines

2012

Trials

1 trial(s) available for erlotinib hydrochloride and Carcinoma, Ovarian Epithelial

ArticleYear
Randomized phase III study of erlotinib versus observation in patients with no evidence of disease progression after first-line platin-based chemotherapy for ovarian carcinoma: a European Organisation for Research and Treatment of Cancer-Gynaecological Ca
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2014, Feb-01, Volume: 32, Issue:4

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Ovarian Epithelial; Disease-Free Survival; Drug Administration Schedule; Drug Eruptions; ErbB Receptors; Erlotinib Hydrochloride; Europe; Fallopian Tube Neoplasms; Female; Follow-Up Studies; Humans; Immunohistochemistry; In Situ Hybridization, Fluorescence; Kaplan-Meier Estimate; Maintenance Chemotherapy; Middle Aged; Mutation; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Peritoneal Neoplasms; Platinum Compounds; Protein Kinase Inhibitors; Quality of Life; Quinazolines; Signal Transduction; Watchful Waiting

2014

Other Studies

1 other study(ies) available for erlotinib hydrochloride and Carcinoma, Ovarian Epithelial

ArticleYear
EGFR Blockade Reverses Cisplatin Resistance in Human Epithelial Ovarian Cancer Cells.
    Iranian biomedical journal, 2020, Volume: 24, Issue:6

    Topics: Apoptosis; Carcinoma, Ovarian Epithelial; Cell Line, Tumor; Cisplatin; Drug Resistance, Neoplasm; Drug Synergism; ErbB Receptors; Erlotinib Hydrochloride; Female; Gene Expression Regulation, Neoplastic; Humans; Ligands; MAP Kinase Kinase Kinases; Ovarian Neoplasms; Signal Transduction

2020